Goldman Sachs’s Puma Biotechnology PBYI Stock Holding History

Goldman Sachs’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-40,800	Closed	-$4.03M	–	6264
2017 Q4	$4.03M	Hold	40,800	–	–	﹤0.01%	3208
2017 Q3	$4.89M	Buy	40,800 +27,000	+196%	+$2.51M	﹤0.01%	3167
2017 Q2	$1.21M	Buy	+13,800	New	+$772K	﹤0.01%	4289
2016 Q2	–	Sell	-23,600	Closed	-$693K	–	7185
2016 Q1	$693K	Sell	23,600 -85,800	-78%	-$3.88M	﹤0.01%	4419
2015 Q4	$8.58M	Buy	109,400 +12,400	+13%	+$973K	﹤0.01%	2368
2015 Q3	$7.31M	Buy	97,000 +67,000	+223%	+$6.34M	﹤0.01%	2536
2015 Q2	$3.5M	Sell	30,000 -9,700	-24%	-$1.76M	﹤0.01%	3276
2015 Q1	$9.37M	Buy	39,700 +30,000	+309%	+$6.41M	﹤0.01%	2346
2014 Q4	$1.84M	Buy	9,700 +5,200	+116%	+$1.15M	﹤0.01%	3930
2014 Q3	$1.07M	Sell	4,500 -69,100	-94%	-$14.2M	﹤0.01%	4539
2014 Q2	$4.86M	Buy	+73,600	New	+$5.23M	﹤0.01%	3066

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Goldman Sachs's PBYI Position: Q1 2026 in Review

Goldman Sachs reduced its Puma Biotechnology (PBYI) stake by 16% in Q1 2026, selling an estimated $801K and leaving 669,719 shares worth $4.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3858.

Goldman Sachs first reported a position in PBYI in Q2 2013 and has held it in 52 quarters since. The position peaked at $59.7M in Q3 2017. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

Goldman Sachs held 669,719 shares of Puma Biotechnology worth $4.28M as of Q1 2026.
Goldman Sachs sold 124,243 Puma Biotechnology shares in Q1 2026, an estimated $801K.
Puma Biotechnology made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3858 holding.
Goldman Sachs first reported a position in Puma Biotechnology in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's Puma Biotechnology position peaked at $59.7M in Q3 2017.
157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.